title: [Use of adriamycin in the treatment of metastatic breast cancer].
abstract: Adriamycin (alone and as a component of FAC scheme) should be administered to patients with disseminated breast cancer resistant to cytostatic drugs. This treatment is followed by remission and arrests the process for an average of 9 months (in some cases up to 30 months). Mean doses of 30-40 mg should be given to outpatients on days 1 and 8 of each course, with intervals between courses being 21-28 days. No apparent side-effects are observed. The total dose should be as high as 450-550 mg. Adjuvant antiestrogen treatment (tamoxifen) should be given to pre- and menopausal patients.
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D002369:Castration; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008408:Mastectomy; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D013997:Time Factors
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
vernacular_title: Lechenie metastaticheskikh form raka molochnoĭ zhelezy s ispol'zovaniem adriamitsina.